Table 1

Baseline sociodemographic and clinical characteristics

CharacteristicN=2696
Months of follow-up, mean (SD)52.0 (32.5)
Age in years, median (IQR)57.1 (46.4, 66.7)
Gender, n (%)
Female1468 (54.5)
Male1228 (45.5)
Ethnicity, n (%)
White2256 (83.7)
South Asian255 (9.5)
Black73 (2.7)
Mixed or other88 (3.3)
Unknown24 (0.9)
Comorbidities, n (%)
Obesity*1206 (44.7)
Hypertension1274 (47.3)
T2DM1104 (40.9)
CVD517 (19.2)
Metabolic syndrome†448 (16.6)
Chronic kidney disease, stages 3–5290 (10.8)
Polycystic ovary syndrome94 (3.5)
DCSI‡ score, mean (SD)1.6 (1.7)
Smoking status, n (%)
Non-smoker1437 (53.3)
Current smoker202 (7.5)
Ex-smoker746 (27.7)
Current or ex-smoker§290 (10.8)
Unknown21 (0.8)
Townsend deprivation quintile, n (%)
1 (least deprived)521 (19.3)
2509 (18.9)
3500 (18.5)
4545 (20.2)
5 (most deprived)619 (23.0)
Charlson Comorbidity Index score, n (%)
0132 (4.9)
1–21511 (56.0)
3–4848 (31.5)
≥5205 (7.6)
Elixhauser Comorbidity Index score, n (%)
0573 (21.3)
1–21048 (38.9)
3–4667 (24.7)
≥5408 (15.1)
Number of all-cause hospital admissions per patient in the year before index, mean (SD)2.6 (6.9)
All-cause healthcare costs per patient in the year before index, mean (SD)£4786 (£5874)
  • *BMI≥30 kg/m2; this differs from the overweight/obese group, which included BMI≥25 kg/m2.

  • †Defined as the presence of at least three of the following conditions: obesity based on BMI, diagnosed hypertension, lowered HDL-cholesterol (<40 mg/dL in men or <50 mg/dL in women), elevated triglycerides (>150 mg/dL), and T2DM.

  • ‡Among those with evidence of diabetes (coded diagnosis or ≥2 prescriptions of an antidiabetic treatment (oral glucose-lowering drugs or insulin)).

  • §Defined where the status was ambiguous; it does not reflect the sum of the current and ex-smoker categories.

  • BMI, Body Mass Index; CVD, cardiovascular disease; DCSI, Diabetes Complications Severity Index; HDL, high-density lipoprotein; T2DM, type 2 diabetes mellitus.